Hoth Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Wayne Linsley was granted 75,000 stock options in Rocket One Inc. as part of the company's equity incentive plan.
NASDAQ
Director David Sarnoff was granted 75,000 stock options in Rocket One Inc. on May 26, 2026.
NASDAQ
Director Christopher Michael Camarra was granted 75,000 stock options in Rocket One Inc. on May 26, 2026.
NASDAQ
Director Jeff Pavell was granted 75,000 stock options in Rocket One Inc. on May 26, 2026.
NASDAQ
Hoth Therapeutics CEO Robb Knie acquired 800,000 shares of common stock and disposed of 310,744 shares for tax purposes.
NASDAQ
Hoth Therapeutics CEO Robb Knie reports the acquisition of 100,000 options in the company, vesting immediately.
NASDAQ
Director Graig Springer reports acquisition of 70,000 Hoth Therapeutics options, vesting immediately, with an exercise price of $1.55.
NASDAQ
Director Jeff Pavell reports acquisition of 25,000 options in Hoth Therapeutics, Inc. on August 19, 2024.
NASDAQ
Director David Sarnoff acquired 25,000 options in Hoth Therapeutics, Inc. on August 19, 2024, which vested immediately.
NASDAQ
Director Graig Springer reports acquisition of options in Hoth Therapeutics, Inc.
NASDAQ
Hoth Therapeutics CEO Robb Knie reports the acquisition of 325,000 options in the company, vesting immediately.
NASDAQ
Director Wayne Linsley acquired 25,000 options in Hoth Therapeutics, Inc. on August 19, 2024, which vested immediately.
NASDAQ
Hoth Therapeutics CEO Robb Knie purchased 25,000 shares of common stock at $0.67 per share on August 16, 2024.